Stock listing
NASDAQ:ELTX Elicio Therapeutics, Inc. Stock
Home listing (NASDAQ) of Elicio Therapeutics, Inc.
Follow Elicio Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ELTX
$1.45 USD -0.14 (-8.8%)
Close on Nov 20, 2026
- Day range
- $1.44 – $1.59 USDNov 20, 2026
- Volume
- 231,624 sharesNov 20, 2026
- Market cap
- $41.05M USDAt the close on Nov 20, 2026 · price × 28.31M shares outstanding
- 52-week range
- $1.25 – $16.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $631,965 USDMedian day 309,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ELTX · Home | $1.45 USD | -0.14 (-8.8%) | 231,624 | $1.47 | $1.59 | $1.44 | $1.59 | Close on Nov 20, 2026 |
| Frankfurt:9HA | €1.25 EUR | -0.17 (-12.0%) | — | €1.35 | €1.35 | €1.25 | €1.42 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ELTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.45 | -0.14 | -8.8% | $1.47 | $1.59 | $1.44 | 231,624 | |
| $1.59 | +0.16 | +11.2% | $1.44 | $1.59 | $1.38 | 549,610 | |
| $1.43 | -0.05 | -3.4% | $1.48 | $1.54 | $1.37 | 449,195 | |
| $1.48 | -0.02 | -1.3% | $1.48 | $1.55 | $1.43 | 209,497 | |
| $1.50 | -0.06 | -3.8% | $1.57 | $1.60 | $1.48 | 327,022 | |
| $1.56 | -0.07 | -4.3% | $1.59 | $1.645 | $1.55 | 232,784 | |
| $1.63 | +0.02 | +1.2% | $1.61 | $1.665 | $1.53 | 357,213 | |
| $1.61 | -0.035 | -2.1% | $1.69 | $1.77 | $1.58 | 197,081 | |
| $1.645 | +0.135 | +8.9% | $1.49 | $1.74 | $1.48 | 219,011 | |
| $1.51 | +0.11 | +7.9% | $1.40 | $1.52 | $1.25 | 756,112 | |
| $1.40 | -0.16 | -10.3% | $1.58 | $1.66 | $1.40 | 281,686 | |
| $1.56 | +0.04 | +2.6% | $1.58 | $1.64 | $1.48 | 289,096 | |
| $1.52 | -0.07 | -4.4% | $1.71 | $1.73 | $1.445 | 516,878 | |
| $1.59 | -0.09 | -5.4% | $1.75 | $1.80 | $1.535 | 330,706 | |
| $1.68 | -0.07 | -4.0% | $1.74 | $1.78 | $1.655 | 183,462 | |
| $1.75 | -0.10 | -5.4% | $1.82 | $1.89 | $1.745 | 135,951 | |
| $1.85 | +0.02 | +1.1% | $1.80 | $1.89 | $1.72 | 216,925 | |
| $1.83 | +0.13 | +7.6% | $1.67 | $1.835 | $1.655 | 342,266 | |
| $1.70 | -0.20 | -10.5% | $1.91 | $1.943 | $1.64 | 422,974 | |
| $1.90 | -0.04 | -2.1% | $1.94 | $1.98 | $1.79 | 464,082 | |
| $1.94 | +0.27 | +16.2% | $1.68 | $1.97 | $1.67 | 515,800 | |
| $1.67 | +0.10 | +6.4% | $1.57 | $1.68 | $1.52 | 269,900 | |
| $1.57 | +0.02 | +1.3% | $1.52 | $1.62 | $1.50 | 275,800 | |
| $1.55 | -0.01 | -0.6% | $1.57 | $1.595 | $1.44 | 298,100 | |
| $1.56 | -0.22 | -12.4% | $1.81 | $1.85 | $1.55 | 333,400 | |
| $1.78 | -0.01 | -0.6% | $1.78 | $1.86 | $1.763 | 169,400 | |
| $1.79 | +0.02 | +1.1% | $1.77 | $1.91 | $1.75 | 373,300 | |
| $1.77 | -0.11 | -5.9% | $1.88 | $1.88 | $1.73 | 232,000 | |
| $1.88 | -0.01 | -0.5% | $1.90 | $1.91 | $1.82 | 164,400 | |
| $1.89 | +0.08 | +4.4% | $1.83 | $1.92 | $1.785 | 306,200 | |
| $1.81 | -0.04 | -2.2% | $1.85 | $1.85 | $1.74 | 267,000 | |
| $1.85 | -0.03 | -1.6% | $1.87 | $1.92 | $1.83 | 138,900 | |
| $1.88 | -0.04 | -2.1% | $1.90 | $1.96 | $1.86 | 259,100 | |
| $1.92 | 0.00 | 0.0% | $1.93 | $1.96 | $1.81 | 200,200 | |
| $1.92 | 0.00 | 0.0% | $1.95 | $1.97 | $1.85 | 175,900 | |
| $1.92 | +0.10 | +5.5% | $1.82 | $1.96 | $1.82 | 310,200 | |
| $1.82 | -0.02 | -1.1% | $1.86 | $1.86 | $1.78 | 274,000 | |
| $1.84 | -0.01 | -0.5% | $1.85 | $1.90 | $1.77 | 452,500 | |
| $1.85 | +0.01 | +0.5% | $1.85 | $1.90 | $1.81 | 222,100 | |
| $1.84 | -0.04 | -2.1% | $1.88 | $1.90 | $1.82 | 165,400 | |
| $1.88 | +0.01 | +0.5% | $1.88 | $2.00 | $1.81 | 339,700 | |
| $1.87 | 0.00 | 0.0% | $1.87 | $1.895 | $1.84 | 195,400 | |
| $1.87 | -0.04 | -2.1% | $1.92 | $1.925 | $1.82 | 402,600 | |
| $1.91 | +0.02 | +1.1% | $1.92 | $2.02 | $1.91 | 483,600 | |
| $1.89 | +0.025 | +1.3% | $1.86 | $2.00 | $1.86 | 689,700 | |
| $1.865 | +0.095 | +5.4% | $1.79 | $1.90 | $1.785 | 340,200 | |
| $1.77 | -0.22 | -11.1% | $1.90 | $1.90 | $1.705 | 629,200 | |
| $1.99 | -0.01 | -0.5% | $2.01 | $2.02 | $1.915 | 319,000 | |
| $2.00 | -0.05 | -2.4% | $2.06 | $2.09 | $1.95 | 391,700 | |
| $2.05 | -0.06 | -2.8% | $2.14 | $2.20 | $2.02 | 445,600 | |
| $2.11 | -0.07 | -3.2% | $2.17 | $2.20 | $2.07 | 343,100 | |
| $2.18 | -0.17 | -7.2% | $2.37 | $2.375 | $2.17 | 457,400 | |
| $2.35 | -0.06 | -2.5% | $2.42 | $2.46 | $2.34 | 324,600 | |
| $2.41 | -0.09 | -3.6% | $2.50 | $2.50 | $2.36 | 487,900 | |
| $2.50 | -0.05 | -2.0% | $2.55 | $2.56 | $2.465 | 272,700 | |
| $2.55 | -0.01 | -0.4% | $2.57 | $2.61 | $2.48 | 397,600 | |
| $2.56 | -0.14 | -5.2% | $2.70 | $2.71 | $2.55 | 334,300 | |
| $2.70 | -0.14 | -4.9% | $2.84 | $2.87 | $2.70 | 412,200 | |
| $2.84 | -0.16 | -5.3% | $3.00 | $3.00 | $2.84 | 421,600 | |
| $3.00 | +0.02 | +0.7% | $3.00 | $3.05 | $2.97 | 131,200 | |
| $2.98 | -0.03 | -1.0% | $3.00 | $3.07 | $2.96 | 181,900 | |
| $3.01 | +0.03 | +1.0% | $3.00 | $3.095 | $2.98 | 223,600 | |
| $2.98 | -0.06 | -2.0% | $3.06 | $3.06 | $2.94 | 309,000 | |
| $3.04 | -0.035 | -1.1% | $3.11 | $3.11 | $3.03 | 279,200 | |
| $3.075 | -0.055 | -1.8% | $3.11 | $3.135 | $3.02 | 207,800 |
Splits
1 split · NASDAQ:ELTX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:ELTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 31 slides
Latest news
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $1.51 (+7.9%) on Nov 6, 2026
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
Nov 4, 2026
Closed $1.56 (+2.6%) on Nov 4, 2026
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Oct 23, 2026
Closed $1.90 (-2.1%) on Oct 23, 2026
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Sep 24, 2026
Closed $1.88 (+0.5%) on Sep 24, 2026
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 31, 2026
Closed $2.70 (-4.9%) on Aug 31, 2026
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Aug 24, 2026
Closed $2.98 (-2.0%) on Aug 24, 2026
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 13, 2026
Closed $3.09 (-1.9%) on Aug 14, 2026
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
Aug 10, 2026
Closed $3.10 (-2.8%) on Aug 10, 2026
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Jul 6, 2026
Closed $2.80 (-15.0%) on Jul 7, 2026
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
Jul 2, 2026
Closed $3.22 (-37.4%) on Jul 2, 2026
Elicio Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 36 in all · newest Nov 5, 2026 · oldest 2025
- Decks
- 15 decks · latest September 2026
Where Elicio Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ELTX · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A3CY4J | LS Exchange | Germany | EUR |
| BOATS:ELTX | BOATS | United States | USD |
| Lang & Schwarz:A3CY4J | Lang & Schwarz | Germany | EUR |
| gettex:9HA | gettex | Germany | EUR |
| Dusseldorf:9HA | Dusseldorf | Germany | EUR |
| Frankfurt:9HA | Frankfurt | Germany | EUR |
| Munich:9HA | Munich | Germany | EUR |
| Tradegate:9HA | Tradegate | Germany | EUR |
Valuation
Price/book 2.2× against a median of 2.8×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $19.78M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 1.81
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.89M | US$32.03M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Dogwood Therapeutics, Inc. · NASDAQ:DWTX | US$39.57M | US$34.74M | n/a | 347× | n/a | 0.6× | n/a | 0.0× | 0.79 |
| Median of the others | US$41.82M | US$32.74M | 48.8× | 93.6× | 2.8× | 38.7% | 0.0× | 1.24 |
Forecasts
2 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 13.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.63 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Robert Connelly | Chief Executive Officer |
| Megan Filoon | General Counsel, Secretary and Compliance Officer |
| Christopher Haqq | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Esther Welkowsky | Senior Vice President, Clinical Development |
| Joy Seymour | Senior Vice President, Head of Regulatory Affairs |
| Marc Wolfgang | Chief Technology Officer |
| Peter DeMuth | Chief Scientific Officer |
| Preetam Shah | Chief Strategy and Financial Officer |
Board
| Director | Role |
|---|---|
| Julian Adams | Chairman |
| Allen R. Nissenson | Director |
| Carol Ashe | Director |
| Jay Venkatesan | Director |
| Karen J. Wilson | Director |
| Robert Connelly | Chief Executive Officer |
| Robert R. Ruffolo | Director |
| Yekaterina Chudnovsky | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +7.9% |
| Q2 2026 | Aug 13, 2026 · After close | −1.9% |
| Q1 2026 | May 11, 2026 · After close | −9.1% |
| Q3 2025 | Nov 13, 2025 · After close | −2.2% |
| Q2 2025 | Aug 7, 2025 · After close | +1.4% |
| Q1 2025 | May 13, 2025 · After close | −5.3% |
| Q4 2024 | Mar 27, 2025 · Before open | −4.1% |
| Q3 2024 | Nov 13, 2024 · After close | +4.8% |
| Q2 2024 | Aug 13, 2024 · After close | −5.3% |
| Q1 2024 | May 15, 2024 · After close | −9.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 29, 2024 · Before open | −6.3% |
| Q3 2023 | Nov 9, 2023 · After close | −0.3% |
| Q2 2023 | Aug 11, 2023 · Before open | 0.0% |
| Q1 2023 | May 10, 2023 · After close | −6.0% |
| Q4 2022 | Mar 29, 2023 | +12.5% |
| Q3 2022 | Nov 14, 2022 | −12.3% |
| Q2 2022 | Aug 16, 2022 | −1.9% |
| Q1 2022 | May 17, 2022 | −15.4% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 | −5.6% |
| Quarter to Jun 30, 2021 | Jul 13, 2021 | −7.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 31 slides | September 2026 |
| Technical Presentation (June 2026) | Technical | 23 slides | Jun 24, 2026 |
| Corporate Update (June 2026) | Corporate update | 16 slides | Jun 15, 2026 |
| Investor Presentation (January 2026) | Investor deck | 50 slides | January 2026 |
| Technical Presentation (September 2025) | Technical | 12 slides | Sep 17, 2025 |
| Investor Presentation (August 2025) | Investor deck | 46 slides | August 2025 |
| Investor Presentation (May 2025) | Investor deck | 52 slides | May 2025 |
| Investor Presentation (January 2025) | Investor deck | 31 slides | Jan 23, 2025 |
| Investor Presentation (December 2024) | Investor deck | 32 slides | Dec 12, 2024 |
| Investor Presentation (June 2024) | Investor deck | 40 slides | June 2024 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2024) | Investor deck | 24 slides | January 2024 |
| Technical Presentation (December 2023) | Technical | 17 slides | Dec 1, 2023 |
| Investor Presentation (September 2023) | Investor deck | 25 slides | Sep 28, 2023 |
| Investor Presentation (June 2023) | Investor deck | 21 slides | June 2023 |
| Angion Biomedica — Merger or Acquisition (January 2023) | Merger or acquisition | 22 slides | Jan 18, 2023 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock Closed: US$15M in the latest tranche · Titan Partners, a division of American Capital Partners +1 Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc. Use of proceeds: Support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the pipeline | Aug 13, 2026 |
| Registered direct offering of common stock Announced: about US$15M · Titan Partners, a division of American Capital Partners +1 Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc. Use of proceeds: Fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, the pipeline and platform, working capital and general corporate purposes | Jul 2, 2026 |
| At-the-market programme of shares under at-the-market program Tranche closed: US$11.1M raised | Nov 13, 2025 |
| Senior secured promissory note with warrants Closed: US$10M raised · Warrants at US$7.75 for 60 months Buyers: GKCC, LLC (existing investor; $10 million senior secured promissory note and warrants to purchase 103,225 shares) Use of proceeds: With existing cash, to support operations into Q1 2026, beyond the AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025 | Jun 4, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Angion Biomedica Corp. Priced at US$16.00 a share on Feb 4, 2021.
- Price
- US$16.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$80 million
- Underwriters' option
- Up to 750,000 more shares
- Listing
- ANGN on the Nasdaq Global Select Market
- Underwriters
- Cowen, Stifel, H.C. Wainwright & Co., Oppenheimer & Co. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2020 |
| Filed publicly | Jan 15, 2021 |
| Amended twice | Newest Feb 4, 2021 |
| Shares registered with an exchange | Feb 2, 2021 |
| Declared effective by the SEC | Feb 4, 2021 |
| Final prospectus, with the price | Feb 5, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 5, 2021 |
| EFFECT · Notice that a registration is effective | Feb 4, 2021 |
| CERT · Exchange's certificate of listing | Feb 4, 2021 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Feb 4, 2021 |
| S-1/A · Registration statement, amended | Feb 4, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 2, 2021 |
| S-1/A · Registration statement, amended | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Jan 26, 2021 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 15, 2021 |
| S-1 · Registration statement | Jan 15, 2021 |
| UPLOAD · Letter from the SEC | Dec 18, 2020 |
| DRSLTR · Letter to the SEC with a draft | Dec 15, 2020 |
| DRS/A · Draft registration statement, amended | Dec 15, 2020 |
| UPLOAD · Letter from the SEC | May 27, 2020 |
| DRSLTR · Letter to the SEC with a draft | May 13, 2020 |
| DRS/A · Draft registration statement, amended | May 13, 2020 |
| UPLOAD · Letter from the SEC | Mar 10, 2020 |
| DRS · Draft registration statement | Feb 14, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.30M | 28.3M | 2.88M | 1.49M | 4.03M | 6.58M | 7.30M |
| Cost of revenue | 1.13M | 1.18M | 1.17M | 0 | 433.0K | 1.19M | 1.14M | 380.0K | 3.17M | 3.67M |
| Gross profit | -1.13M | -1.18M | -1.17M | -1.06M | 27.1M | 1.06M | 351.0K | 3.65M | 3.41M | 3.62M |
| Research and development | 24.9M | 33.7M | 23.8M | 18.1M | 48.7M | 39.0M | 29.8M | 9.15M | 196.0K | |
| Selling, general and administrative | 12.8M | 11.3M | 11.9M | 5.63M | 7.54M | 3.00M | 2.80M | |||
| Operating income | -37.7M | -45.0M | -35.7M | -23.7M | -39.3M | -55.3M | -38.6M | -14.3M | -397.8K | -419.2K |
| Depreciation and amortization | 204.0K | 321.0K | 382.0K | 390.0K | 91.0K | 98.0K | 496.0K | 2.00K | 460.3K | 463.2K |
| EBITDA | -37.5M | -44.7M | -35.4M | -23.3M | -39.2M | -55.2M | -38.1M | -14.3M | 62.5K | 44.0K |
| Interest expense | 1.13M | 455.0K | 1.06M | 3.60M | 876.4K | 8.85M | 300.4K | 307.4K | ||
| Income before tax | -39.6M | -51.9M | -35.2M | -38.8M | -54.6M | -80.1M | -40.7M | -20.0M | 1.73M | 1.19M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 81.5K | 452.8K | 201.9K | |
| Net income | -39.6M | -51.9M | -35.2M | -28.2M | -54.6M | -80.1M | -40.7M | -20.0M | 632.2K | 307.3K |
| Earnings per share, basic | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 | -5.43 | -4.99 | -6.79 | 103.31 | 50.21 |
| Earnings per share, diluted | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 | -5.43 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 18.6M | 17.6M | 12.9M | 6.16M | 88.8M | 34.6M | 5.57M | 25.5M | 2.06M | 1.40M |
| Receivables | 0 | 806.0K | 5.00M | 440.0K | 107.0K | 485.8K | 580.4K | |||
| Inventory | 4.22M | 189.0K | -4.62M | -63.7K | 1 | |||||
| Current assets | 19.3M | 20.7M | 16.3M | 10.7M | 91.2M | 42.3M | 6.11M | 25.7M | 2.62M | 2.06M |
| Property, plant and equipment | 295.0K | 483.0K | 717.0K | 1.15M | 451.0K | 156.0K | 1.43M | |||
| Total assets | 25.9M | 28.2M | 27.1M | 22.7M | 96.5M | 47.3M | 11.9M | 26.6M | 11.1M | 11.0M |
| Accounts payable | 672.0K | 1.04M | 4.37M | 2.81M | 4.71M | 5.58M | 11.2M | 534.0K | 37.6K | 209.5K |
| Current liabilities | 8.11M | 11.5M | 9.76M | 6.87M | 11.3M | 107.4M | 26.6M | 7.36M | 1.15M | 1.10M |
| Long-term debt | 9.41M | 20.0M | 0 | 635.0K | ||||||
| Total debt | 10.0M | 20.0M | 6.92M | 7.48M | 0 | 635.0K | 10.8M | 5.32M | 5.44M | |
| Total liabilities | 24.2M | 39.5M | 15.8M | 13.7M | 15.0M | 137.8M | 30.5M | 7.72M | 6.60M | 6.79M |
| Shareholders' equity | 1.64M | -11.3M | 11.4M | -102.1M | -74.5M | -90.4M | -18.6M | 18.9M | 2.34M | 1.71M |
| Shares outstanding | 17.8M | 11.0M | 9.60M | 320.3K | 30.0M | 15.3M | 8.15M | 2.95M | 6.12K | 6.12K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -37.0M | -37.1M | -32.7M | -22.2M | -52.6M | -22.9M | -24.6M | -8.02M | 1.89M | 1.07M |
| Capital spending | -16.0K | -87.0K | -66.0K | -654.0K | -382.0K | -41.0K | -242.0K | 0 | -17.6K | -47.7K |
| Free cash flow | -37.0M | -37.2M | -32.8M | -22.8M | -53.0M | -22.9M | -24.8M | -8.02M | 1.87M | 1.02M |
| Cash from investing | -16.0K | -84.0K | -32.0K | -654.0K | -382.0K | -41.0K | -242.0K | -67.6K | -47.7K | |
| Cash from financing | 36.7M | 42.3M | 38.6M | 21.2M | 107.2M | 52.4M | 4.89M | 31.7M | -1.17M | -429.2K |
| Share buybacks | -549.0K | -150.0K | 0 | -36.0K | -375.0K | |||||
| Change in cash | -225.0K | 5.19M | 5.89M | -1.63M | 54.1M | 29.0M | -19.9M | 23.5M | 652.8K | 588.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Oct 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jul 2, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 2, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 24, 2026 | Current report | SEC |
| 8-K · Current report | Jun 17, 2026 | Current report | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2026 | Annual report | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 16, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 16, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| UPLOAD · Letter from the SEC | Mar 6, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 2, 2026 | Offer document | SEC |
| S-3 · Registration statement | Feb 27, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 17, 2025 | Current report | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Aug 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 4, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 8-K · Current report | May 20, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 9, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 9, 2025 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 2, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Mar 24, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 5, 2025 | Financing | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 30, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| 8-K · Current report | Jan 22, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 7, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2024 | Current report | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 22, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Nov 21, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 15, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| 8-K · Current report | Oct 17, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Sep 27, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 27, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 30, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Aug 12, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 28, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 28, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 27, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 12, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jun 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 6, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 3, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jun 3, 2024 | Offer document | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Apr 10, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 5, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2024 | Offer document | SEC |
| S-3 · Registration statement | Mar 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 29, 2024 | Results | SEC |
| D | Mar 28, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 20, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2024 | Material contract | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 17, 2024 | Current report | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| D | Jan 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 27, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 26, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 22, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Nov 3, 2023 | Current report | SEC |
| 8-K · Current report | Oct 20, 2023 | Management or board change | SEC |
| 8-K · Current report | Oct 12, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 27, 2023 | Current report | SEC |
| 8-K · Current report | Sep 7, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 30, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Aug 30, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Aug 21, 2023 | Offer document | SEC |
| 8-K/A · Current report, amended | Aug 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 7, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 14, 2023 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jun 14, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 12, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 12, 2023 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jun 12, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 7, 2023 | Insider trade | SEC |
This page holds 200 of 385 filings. Open Filings
Cap table
Built by 6ix from Elicio Therapeutics, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 28,307,225
- Fully diluted
- 28,307,225
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 28,307,225 | Nov 3, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$7.75 · expire about Jun 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 28,307,225 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Karen J. Wilson Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); Serina Therapeutics, Inc. (Director · Since at least Jan 14, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Vaxart, Inc. (Director · Aug 25, 2020 – Jun 16, 2021 · Past); Jazz Pharmaceuticals plc (SVP, Finance & PAO · Mar 9, 2011 – Mar 5, 2019 · Past) | Director · Since at least Feb 4, 2021 |
| Brian Piekos Other companies: KalVista Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Sep 9, 2024); Disc Medicine, Inc. (CFO · Feb 12, 2021 – May 31, 2022 · Past); AMAG Pharmaceuticals Inc (Chief Financial Officer · Jun 9, 2020 – Nov 16, 2020 · Past) | Chief Financial Officer · Jun 1, 2023 – Feb 1, 2024 · Past |
| Jennifer J. Rhodes Other companies: ACADIA Pharmaceuticals Inc. (Chief Legal Officer and Secretary · Since at least Feb 6, 2024); Adamas Pharmaceuticals Inc (CBO, GC & Compliance Officer · Apr 11, 2016 – Jun 20, 2019 · Past); Medivation Inc (GC & Corporate Secretary · Mar 26, 2013 – Mar 16, 2015 · Past) | See Remarks · Feb 4, 2021 – Mar 2, 2022 · Past |
| Christopher Haqq Other companies: Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Atara Biotherapeutics, Inc. (EVP, R&D & Chief Scientific Of · Oct 15, 2014 – Feb 15, 2019 · Past) | Executive Vice President, Head of Research and Development and Chief Medical Officer · Since at least Jun 1, 2023 |
| Gilbert S. Omenn Other companies: Amesite Inc. (Director · Since at least Sep 25, 2020); Galectin Therapeutics Inc. (Director · Since at least Dec 14, 2017) | Director · Feb 4, 2021 – Jun 9, 2022 · Past |
| Jay Venkatesan Other companies: Serina Therapeutics, Inc. (Director · Since at least Feb 12, 2025); Alpine Immune Sciences Inc (Director · Jul 15, 2022 – Jul 15, 2022 · Past) | Director · Since at least May 20, 2022 |
| Julian Adams Other companies: Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); Palvella Therapeutics, Inc. (Director · Jul 25, 2016 – Jan 25, 2018 · Past) | Chairman · Since at least Jun 1, 2023 |
| Victor F. Ganzi Other companies: Aveanna Healthcare Holdings Inc. (Audit Committee Chair, Independent Director · Since at least Jun 30, 2022); Willis Towers Watson Public Limited Company (Director · May 11, 2022 – Jun 8, 2022 · Past) | Director · May 27, 2022 – Jun 9, 2022 · Past |
| Allen R. Nissenson Other companies: Rockwell Medical, Inc. (Director · Since at least Dec 11, 2020) | Director · Since at least Feb 4, 2021 |
| John F Neylan Other companies: Keryx Biopharmaceuticals Inc (Chief Medical Officer · Apr 22, 2015 – Dec 12, 2018 · Past) | See Remarks · Feb 4, 2021 – Mar 2, 2022 · Past |
All 21 people
| Person | Seat |
|---|---|
| Carol Ashe | Director · Since at least Nov 4, 2026 |
| Esther Welkowsky | Senior Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Itzhak Goldberg | Director · Feb 4, 2021 – Jul 1, 2022 · Past |
| Joy Seymour | Senior Vice President, Head of Regulatory Affairs · Since at least Nov 5, 2026 |
| Marc Wolfgang | Chief Technology Officer · Since at least Nov 19, 2025 |
| Megan Filoon | General Counsel, Secretary and Compliance Officer · Since at least Nov 5, 2026 |
| Peter DeMuth | Chief Scientific Officer · Since at least Jun 1, 2023 |
| Preetam Shah | Chief Strategy and Financial Officer · Since at least Apr 30, 2026 |
| Robert Connelly | Chief Executive Officer · Since at least Jun 1, 2023 |
| Robert R. Ruffolo | Director · Since at least Nov 5, 2026 |
| Yekaterina Chudnovsky | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Elicio Therapeutics, Inc.